The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics
Ricarda Evens, Tomislav Majić, Timo Torsten Schmidt, Marianna E. Schmidt
Therapeutic Advances in Psychopharmacology 2023 DOI: 10.1177/20451253231172254 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Systematic review Peer reviewed |
|---|---|
| Sample size | 1,774 |
| Population | Human adults |
| Interventions | LSD psilocybin DMT 5-MeO-DMT mescaline ayahuasca |
| Duration | 1 day to 1 month after drug use |
| Topics | Anxiety Psilocybin Serotonin |
| Keywords | Hallucinogen Adverse effect Clinical psychology Mood |
| Citations | 49 |
| Key findings | Classic serotonergic psychedelics are associated with a subacute 'afterglow' phenomenon comprising beneficial changes in perception and reductions in psychopathological symptoms, with mild to moderate adverse effects and no serious adverse events reported. |
Abstract
Background: Classic serotonergic psychedelics have anecdotally been reported to show a characteristic pattern of subacute effects that persist after the acute effects of the substance have subsided. These transient effects, sometimes labeled as the ‘psychedelic afterglow’, have been suggested to be associated with enhanced effectiveness of psychotherapeutic interventions in the subacute period.
Objectives: This systematic review provides an overview of subacute effects of psychedelics.
Methods: Electronic databases (MEDLINE, Web of Science Core Collection) were searched for studies that assessed the effects of psychedelics (LSD, psilocybin, DMT, 5-MeO-DMT, mescaline, or ayahuasca) on psychological outcome measures and subacute adverse effects in human adults between 1950 and August 2021, occurring between 1 day and 1 month after drug use.
Results: Forty-eight studies including a total number of 1,774 participants were eligible for review. Taken together, the following subacute effects were observed: reductions in different psychopathological symptoms; increases in wellbeing, mood, mindfulness, social measures, spirituality, and positive behavioral changes; mixed changes in personality/values/attitudes, and creativity/flexibility. Subacute adverse effects comprised a wide range of complaints, including headaches, sleep disturbances, and individual cases of increased psychological distress.
Discussion: Results support narrative reports of a subacute psychedelic ‘afterglow’ phenomenon comprising potentially beneficial changes in the perception of self, others, and the environment. Subacute adverse events were mild to severe, and no serious adverse events were reported. Many studies, however, lacked a standardized assessment of adverse effects. Future studies are needed to investigate the role of possible moderator variables and to reveal if and how positive effects from the subacute window may consolidate into long-term mental health benefits.
Comparable studies
Other systematic reviews and meta-analyses on psilocybin for anxiety, most cited first.
Citations in the library
Cited by 45
- Who are you after psychedelics? A systematic review and a meta-analysis of the magnitude of long-term effects of serotonergic psychedelics on cognition/creativity, emotional processing and personality Neuroscience & Biobehavioral Reviews February 3, 2024
- Autonomic nervous system activity correlates with peak experiences induced by DMT and predicts increases in well-being. Journal of Psychopharmacology October 1, 2024
- Cognitive functioning associated with acute and subacute effects of classic psychedelics and MDMA - a systematic review and meta-analysis. Scientific Reports June 26, 2024
- Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression JAMA Psychiatry March 18, 2026
- Alternative beliefs in psychedelic drug users Scientific Reports September 30, 2023
and 40 more in the library
Cites 77
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
and 72 more in the library